Biopharmaceutical leader Kiniksa Pharmaceuticals (KNSA) is approaching a new buy point in the wake of a strong quarterly sales report. That makes Kiniksa stock Thursday's pick for IBD 50 Growth Stocks To Watch from Investor's Business Daily. Kiniksa develops and commercializes medicines for cardiovascular, autoimmune and autoinflammatory diseases. Its only drug, Arcalyst, treats recurrent pericarditis, a condition in which the…
Biopharmaceutical Leader Kiniksa Poised To Hit New Buy Point After Big Revenue Beat
Kaynak: Yahoo Finance
İlgili Haberler
Global
CoreWeave Is My Top IPO Pick Right Now: Over 75% of Its Revenue Is Locked In Through Contracts
Yahoo Finance · 3 saat önce
Global
Why Treasury’s $6 billion bond buyback didn’t lower mortgage rates
Yahoo Finance · 3 saat önce
Global
US consumer prices accelerate in August, push Fed closer to rate hike
Yahoo Finance · 4 saat önce
Global
Affirm Rallies 5% as Midweek Selloff Unwinds; Klarna and PayPal Tick Up
Yahoo Finance · 4 saat önce
Global
‘The Largest IPO Ever, Surpassing SpaceX’: Anthropic Is Up Next
Yahoo Finance · 4 saat önce
Yorumlar (0)
Giriş yaparak yorum yazabilirsin.
İlk yorumu sen yaz.